Marker Therapeutics' Phase 1 APOLLO study shows lymphodepletion significantly improves expansion and persistence of MT-601 MAR-T cells in lymphoma patients, potentially enhancing anti-tumor activity.
Marker Therapeutics' lead MAR-T cell therapy MT-601 (neldaleucel) demonstrated a 78% objective response rate in lymphoma patients who relapsed after anti-CD19 CAR-T therapy, with 44.4% achieving complete responses.
Marker Therapeutics has provided a clinical update on its Phase 1 APOLLO study of MT-601, showing positive outcomes in patients with lymphoma who have relapsed after CD19 CAR-T cell therapy. The study highlights the potential of MT-601 to address a significant unmet medical need, with observed objective responses in heavily pre-treated patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.